Please login to the form below
Pneumococcal vaccine
This page shows the latest Pneumococcal vaccine news and features for those working in and with pharma, biotech and healthcare.
MSD’s Vaxneuvance approved by MHRA for prevention of pneumococcal diseases in children
As the first new pneumococcal conjugate vaccine (PCV) in over a decade, we hope to see the new generation of pneumococcal vaccines assessed holistically by the UK health system,” Herath added. ... a catch-up setting for older children who are either
Latest news
-
FDA delays Merck’s pneumococcal vaccine Vaxneuvance
pneumococcal vaccine Vaxneuvance to 1 July 2022. ... After Merck’s 15-strain pneumococcal vaccine was approved by the FDA on 16 July 2021, the company hoped it could compete with Pfizer’s FDA-approved 20-strain pneumococcal vaccine,
-
Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab
Pfizer has launched a new study of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) along with a booster dose of its BioNTech-partnered COVID-19 jab. ... 20vPnC includes capsular polysaccharide conjugates for the 13 serotypes in Pfizer’s
-
Merck wins speedy FDA review for 15-valent pneumococcal vaccine
Merck &Co (MSD) has been given a fast-track designation for its next-generation 15-valent pneumococcal conjugate vaccine candidate V114. ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13, although Pfizer is seeking to
-
Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA
For more than a century, Merck inventors have developed vaccines that help tackle some of society’s biggest public health challenges, and that heritage is reflected today in our pneumococcal vaccine ... Pfizer also announced results from a
-
Keytruda growth helps Merck to offset COVID-19 impact in Q3
The growth in profits was mainly due to increasing demand for certain drugs, including its blockbuster checkpoint inhibitor Keytruda (pembrolizumab), and its bacterial pneumonia vaccine. ... While sales of its papillomavirus vaccine Gardasil declined due
More from news
Approximately 2 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
-
Deal Watch table for March 2014
26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.
-
A tailored approach to the BRIC markets
In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in ... Europe. The deal guaranteed GSK a set price and set volumes for the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
